Terns Pharmaceuticals, Inc.
DelistedCIK 1831363fmd_0MKW6KJJ8BAR6WGD4PFBA6RF9KManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Dec 31, 2025, 24 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Total revenues | 0 | 1 | 0 | – | – | – |
| Research and development | 28 | 31 | 40 | 63 | 70 | 78 |
| Operating income | (37) | (50) | (62) | (103) | (102) | (110) |
| Other non-operating income (expense) | (3) | 0 | 2 | 13 | 13 | 14 |
| Income before taxes | (40) | (50) | (60) | (90) | (89) | (96) |
| Income tax expense | 1 | 1 | 0 | 0 | 0 | 1 |
| Net income from continuing operations | (41) | (50) | (60) | (90) | (89) | (96) |
| Net income | (40) | (50) | (60) | (90) | (89) | (96) |
| Net income to common shareholders | (29) | (50) | – | – | – | – |